Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking

New England Journal of Medicine

Volumn 340, Issue 25, 1999, Pages 1948-1953

  Pauwels, Romain A ^a   Löfdahl, Claes Göran ^b   Laitinen, Lauri A ^c   Schouten, Jan P ^d   Postma, Dirkje S ^e   Pride, Neil B ^f   Ohlsson, Stefan V ^g  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d UNIVERSITY OF GRONINGEN   (Netherlands)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f HAMMERSMITH HOSPITAL   (United Kingdom)

^g Clinical Research and Development   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE;

ADULT; AGED; ARTICLE; BRONCHODILATATION; CAPILLARY RESISTANCE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FORCED EXPIRATORY VOLUME; FRACTURE; HOARSENESS; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; INHALATIONAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SMOKING; STEROID THERAPY; THRUSH; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADULT; AGED; BRONCHODILATOR AGENTS; BUDESONIDE; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOCORTICOIDS; HUMANS; LUNG DISEASES, OBSTRUCTIVE; MALE; MIDDLE AGED; SMOKING;

EID: 0345188819     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199906243402503     Document Type: Article

References (34)

1. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the Lung Health Study. JAMA 1994;272:1497-505.
2. Silagy C, Mant D, Fowler G, Lodge M. Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation. Lancet 1994;343:139-42.
3. Saetta M, Finkelstein R, Cosio MG. Morphological and cellular basis for airflow limitations in smokers. Eur Respir J 1994;7:1505-15.
4. Jeffery PK. Structural and inflammatory changes in COPD: a comparison with asthma. Thorax 1998;53:129-36.
5. Global Initiative for Asthma. Global strategy for asthma management and prevention. Washington, D.C.: National Heart, Lung, and Blood Institute, 1995. (NIH publication no. 95-3659.)
6. Llewellyn-Jones CG, Harris TAJ, Stockley RA. Effect of fluticasone propionate on sputum of patients with chronic bronchitis and emphysema. Am J Respir Crit Care Med 1996;153:616-21.
7. Keatings VM, Jatakanon A, Worsdell YM, Barnes PJ. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997;155:542-8.
8. Thompson AB, Mueller MB, Heires AJ, et al. Aerosolized beclomethasone in chronic bronchitis: improved pulmonary function and diminished airway inflammation. Am Rev Respir Dis 1992;146:389-95.
9. Confalonieri M, Mainardi E, Della Porta R, et al. Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease. Thorax 1998;53:583-5.
10. Pauwels RA, Lofdahl CG, Pride NB, Postma DS, Laitinen LA, Ohlsson SV. European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): hypothesis and design. Eur Respir J 1992;5: 1254-61.
11. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows: report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal: official statement of the European Respiratory Society. Eur Respir J Suppl 1993;16:5-40.
12. American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 1995;152:1107-36.
13. Liberman UA, Weiss SR, Broii J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-43.
14. Renkema TEJ, Schouten JP, Koeter GH, Postma DS. Effects of long-term treatment with corticosteroids in COPD. Chest 1996;109:1156-62.
15. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982;38:963-74.
16. Davidian M, Giltinan DM. Nonlinear models for repeated measurement data. London: Chapman &Hall, 1995.
17. Pinheiro JC, Bates DM. LME and NLME: mixed effects models: methods and classes for S and Splus (1.2) PC Windows. Madison: University of Wisconsin, 1995.
18. Akaike H. Statistical predictor identification. Ann Inst Stat Math 1970: 203-17.
19. Burrows B. Predictors of loss of lung function and mortality in obstructive lung diseases. Eur Respir Rev 1991;1:340-5.
20. Pride NB, Burrows B. Development of impaired lung function: natural history and risk factors. In: Calverlcy PMA, Pride NB, eds. Chronic obstructive pulmonary disease. London: Chapman & Hall Medical, 1995:69-91.
21. Weir DC, Burge PS. Effects of high dose inhaled beclomethasone dipropionate, 750 micrograms and 1500 micrograms twice daily, and 40 mg per day oral prednisolone on lung function, symptoms, and bronchial hyperresponsiveness in patients with non-asthmatic chronic airflow obstruction. Thorax 1993;48:309-16.
22. Kerstjens HAM, Brand PLP, Hughes MD, et al. A comparison of bronchodilator therapy with or without inhaled corticostcroid therapy for obstructive airways disease. N Engl J Med 1992;327:1413-9.
23. Dompeling E, van Schayck CP, Molema J, Folgering H, van Grunsven PM, van Weel C. Inhaled beclomethasone improves the course of asthma and COPD. Eur Respir J 1992;5:945-52.
24. Auffarth B, Postma DS, de Monchy JG, van der Mark TW, Boorsma M, Koeter GH. Effects of inhaled budesonide on spirometric values, reversibility, airway responsiveness, and cough threshold in smokers with chronic obstructive lung disease. Thorax 1991;46:372-7.
25. Callahan CM, Dittus RS, Katz BP. Oral corticosteroid therapy for padents with stable chronic obstructive pulmonary disease: a meta-analysis. Ann Intern Med 1991;114:216-23.
26. Watson A, Lim TK, Joyce H, Pride NB. Failure of inhaled corticosteroids to modify bronchoconstrictor or bronchodilator responsiveness in middle-aged smokers with mild airflow obstruction. Chest 1992;101:350-5.
27. Engel T, Heinig JM, Madsen O, Hansen M, Weeke ER. A trial of inhaled budesonidc on airway responsiveness in smokers with chronic bronchitis. Eur Respir J 1989;2:935-9.
28. Eliasson O, Hoffman J, Trueb D, Frederick D, McCormick JR. Corticosteroids in COPD: a clinical trial and reassessment of the literature. Chest 1986;89:484-90.
29. Paggiaro PL, Dahle K, Bakran I, Frith L, Hollingworth K, Efthimiou J. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet 1998;351:773-80. [Erratum, Lancet 1998;351:1968.]
30. Postma DS, Steenhuis EJ, van der Weele LT, Sluiter HJ. Severe chronic airflow obstruction: can corticosteroids slow down progression? Eur J Respir Dis 1985;67:56-64.
31. Postma DS, Peters I, Steenhuis EJ, Sluiter HJ. Moderately severe chronic airflow obstruction: can corticosteroids slow down progression? Eur Respir J 1988;1:22-6.
32. Dompeling E, van Schayck CP, van Grunsven PM, et al. Slowing the deterioration of asthma and chronic obstructive pulmonary disease observed during bronchodilator therapy by adding inhaled corticosteroids: a 4-year prospective study. Ann Intern Med 1993;118:770-8.
33. Capewell S, Reynolds S, Shuttleworth D, Edwards C, Finlay AY. Purpura and dermal thinning associated with high dose inhaled corticosteroids. BMJ 1990;300:1548-51.
34. Mak VHF, Melchor R, Spiro SG. Easy bruising as a side-effect of inhaled corticosteroids. Eur Respir J 1992;5:1068-74.